chitosan has been researched along with scutellarin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Deng, DY; Huang, P; Long, L; Luo, J; Tan, J; Wang, J; Yang, L; Zhang, LM; Zhou, W; Zhu, B | 1 |
| Ho, PC; Liu, S | 1 |
2 other study(ies) available for chitosan and scutellarin
| Article | Year |
|---|---|
Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.
Topics: Administration, Oral; Animals; Apigenin; Biological Availability; Caco-2 Cells; Chitosan; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Drug Carriers; Drugs, Chinese Herbal; Erigeron; Glucuronates; Humans; Male; Nanoparticles; Rats, Sprague-Dawley; Retinal Vessels; Vascular Endothelial Growth Factor A; Vitamin B 12; Zebrafish | 2017 |
Intranasal administration of brain-targeted HP-β-CD/chitosan nanoparticles for delivery of scutellarin, a compound with protective effect in cerebral ischaemia.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Intranasal; Animals; Apigenin; Biological Availability; Brain; Brain Ischemia; Chemistry, Pharmaceutical; Chitosan; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Glucuronates; Half-Life; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Solubility; Tissue Distribution | 2017 |